Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism
NCT04263038
Anticoagulant-induced Bleeding, Bleeding
Woluwe-Saint-Lambert, Brussels Capital, Belgium
View Trial DetailsNCT Number: NCT06679777
In the Swedish CArdioPulmonary bioImage Study (SCAPIS 1), 30,154 randomly selected men and women, aged 50-64 years, were recruited from six areas in Sweden during 2013-2018. The study population was investigated with CCTA, ultrasound carotids, physical examination, questionnaires, accelerometry, ECG, spirometry, and biochemical markers. The aim was to obtain new information relevant to the identification and treatment of individuals with cardiopulmonary and metabolic diseases and to optimize the possibilities for studying disease mechanisms.
In SCAPIS-2, half of the individuals (n≈15,000) included in SCAPIS 1, will be re-examined 2024-2025 with the same investigations as during 2013-2018 except for ultrasound of the carotids.
Interested in participating?
Request InfoAll sexes
Observational
Gothenburg University, Gothenburg, Sweden
The overall aim of SCAPIS is to improve prediction and prevention of cardiovascular and lung disease in the general population by identifying novel risk markers. This is also the purpose of SCAPIS 2, which further aims to gain important insights into risk factors and longitudinal development of heart, vascular and lung diseases such as atherosclerosis and chronic obstructive pulmonary disease. SCAPIS 2 will investigate 15,000 study participants approximately 8-10 years after the baseline examination SCAPIS 1.
The five overall objectives of SCAPIS 2 are:
SCAPIS 2 will recruit approximately 15,000 subjects randomly selected from the baseline examination (SCAPIS 1) study population approximately 8-10 years after their initial participation. During the SCAPIS 1 random samples of men and women aged 50-64 years were drawn from each recruitment area in the Swedish population registry until approximately 30 000 subjects were included. The final number was 30 154 subjects with an even sex and age distribution. The original recruitment process ensured that the study population in SCAPIS 1 was representative for the Swedish population in general.
An invitation letter with brief information about SCAPIS 2 will be sent to randomly selected individuals by mail, including phone number and e-mail address to the study center. The invitation letter will refer to a study webpage where the subjects can indicate if they are interested in participating in SCAPIS 2 and read the subject information in advance (voluntary). The invitation also includes contact information to the study center to be used if the subject prefers to not use the web page or has questions. Subjects that have moved since their participation in SCAPIS 1 will be invited to the same study center as their baseline examination.
The examinations will be performed during 2-3 days within approximately 2 weeks. Whenever possible, all visits should be performed within a period of 4 weeks. Examinations that are common for all sites include:
All subjects will be fasting overnight (at least 8 hours) before the first visit. If a subject has not been fasting overnight, blood sampling should be rescheduled and performed preferably at an extra visit but no later than Visit 2. For subjects with elevated plasma glucose levels, an overnight fasting glucose measurement will be repeated.
Subjects should be instructed to take their regular medication as usual also when fasting. The only medication that should not be taken is medication for diabetes, per oral as well as injections. Subjects with diabetes should be fasting as all other subjects and should bring their medication to take when having breakfast at the clinic. To obtain standardized conditions for the CT examination, subjects are recommended to be fasting for at least 4 hours before intake of a standardized meal. The standardized meal should be consumed 2 hours before the CT scan.
All clinical findings and assessment of risk should be taken care of according to current guidelines and SCAPIS manual.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Through study completion, an average of 5 years
Cardiovascular death, non-fatal myocardial infarction or stroke.
Time frame: Through study completion, an average of 5 years
Cardiovascular death or non-fatal myocardial infarction
Time frame: Through study completion, an average of 5 years
Cardiovascular death
Time frame: Through study completion, an average of 5 years
Myocardial infarction (fatal or non-fatal)
Time frame: Through study completion, an average of 5 years
Stroke (fatal or non-fatal)
Time frame: Through study completion, an average of 5 years
Death (all-cause)
Time frame: Through study completion, an average of 5 years
Unstable angina requiring revascularization
Time frame: Through study completion, an average of 5 years
Chronic obstructive pulmonary disease (COPD)
Time frame: Through study completion, an average of 5 years
Lung cancer
Contact information is provided by the study sponsor or research team.
Tomas Jernberg, PhD
CONTACT
Vibeke Sparring, PhD
CONTACT
Karolinska Institutet
Other
Acronym: SCAPIS2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04263038
Anticoagulant-induced Bleeding, Bleeding
Woluwe-Saint-Lambert, Brussels Capital, Belgium
View Trial DetailsNCT07333183
Cardiovascular Diseases, Fibrosis
Kissimmee, Florida, United States
View Trial DetailsNCT03225586
Behavior, Cancer
Rosario, Santa Fe Province, Argentina
View Trial DetailsNCT03626688
Cardiovascular Diseases, Connective Tissue Diseases
Birmingham, Alabama, United States
View Trial Details